Precision medicine has advanced significantly over the past decade, driven by breakthroughs in chemical, hardware, software, and especially cloud computing technologies. 18 March 2025
MeiraGTx has entered into a strategic partnership with artificial intelligence firm Hologen to accelerate the Phase III development of AAV-GAD, a gene therapy for Parkinson’s disease. 13 March 2025
Insilico Medicine has raised $110 million in a series E funding round to drive the development of its artificial intelligence-powered drug candidates, including its leading drug for idiopathic pulmonary fibrosis (IPF). 13 March 2025
Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, following the implementation of Veeva Systems' Development Cloud. 12 March 2025
Nona Biosciences has introduced Hu-mAtrIx, an AI-assisted drug discovery platform designed to accelerate the identification and development of antibody-based therapies. 7 March 2025
The new US President has repealed an executive order from October 2023, signed by the Biden administration, that sought to establish rigorous safeguards for artificial intelligence (AI) development. 22 February 2025
US biopharma Incyte and privately-held AI-focused biotech Genesis Therapeutics have entered into a strategic collaboration focused on the research, discovery and development of novel small molecule medicines. 21 February 2025
French pharmaceutical company Servier and Google Cloud have announced an expanded five-year partnership aimed at leveraging artificial intelligence (AI) and generative AI to accelerate drug research and development. 16 January 2025
A collection of some of the largest US health systems, in collaboration with the Regeneron Genetics Center, have announced the launch of the Truveta Genome Project. 16 January 2025
Privately-held Italian drugmaker Menarini and its oncology-focused subsidiary Stemline Therapeutics have entered into a licensing deal with AI-driven biotech Insilico Medicines. 15 January 2025
Dyno Therapeutics, a privately-held US genetic technologies company applying AI to enable in vivo gene delivery, has announced that Roche has exercised its option to license a novel capsid for use in a gene therapy program for an undisclosed neurological disease indication. 13 January 2025
Belgian biopharmaceutical company UCB has entered into a license agreement with Ailux Biologics, the biologics discovery division of XtalPi, to leverage its AI platform. 9 January 2025
Insilico Medicine, a biotechnology firm specializing in artificial intelligence-powered drug discovery, has raised over $100 million in a series E funding round. 8 January 2025
The market for artificial intelligence (AI) in cancer care is projected to grow from $2.2 billion in 2024 to $6.3 billion by 2029, reflecting a growth rate of 23.1%, according to a recent study by BCC Research. 31 December 2024
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 20 December 2024
Shanghai-based Fangzhou, has entered into a strategic partnership with the Chinese business of Bristol Myers Squibb China, with the goal of enhancing digital platforms for chronic disease management. 19 December 2024
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Precision medicine has advanced significantly over the past decade, driven by breakthroughs in chemical, hardware, software, and especially cloud computing technologies. 18 March 2025
MeiraGTx has entered into a strategic partnership with artificial intelligence firm Hologen to accelerate the Phase III development of AAV-GAD, a gene therapy for Parkinson’s disease. 13 March 2025
Insilico Medicine has raised $110 million in a series E funding round to drive the development of its artificial intelligence-powered drug candidates, including its leading drug for idiopathic pulmonary fibrosis (IPF). 13 March 2025
Germany’s Boehringer Ingelheim has launched the One Medicine Platform, a new system designed to streamline drug development, following the implementation of Veeva Systems' Development Cloud. 12 March 2025
Nona Biosciences has introduced Hu-mAtrIx, an AI-assisted drug discovery platform designed to accelerate the identification and development of antibody-based therapies. 7 March 2025
The new US President has repealed an executive order from October 2023, signed by the Biden administration, that sought to establish rigorous safeguards for artificial intelligence (AI) development. 22 February 2025
US biopharma Incyte and privately-held AI-focused biotech Genesis Therapeutics have entered into a strategic collaboration focused on the research, discovery and development of novel small molecule medicines. 21 February 2025
French pharmaceutical company Servier and Google Cloud have announced an expanded five-year partnership aimed at leveraging artificial intelligence (AI) and generative AI to accelerate drug research and development. 16 January 2025
A collection of some of the largest US health systems, in collaboration with the Regeneron Genetics Center, have announced the launch of the Truveta Genome Project. 16 January 2025
Privately-held Italian drugmaker Menarini and its oncology-focused subsidiary Stemline Therapeutics have entered into a licensing deal with AI-driven biotech Insilico Medicines. 15 January 2025
Dyno Therapeutics, a privately-held US genetic technologies company applying AI to enable in vivo gene delivery, has announced that Roche has exercised its option to license a novel capsid for use in a gene therapy program for an undisclosed neurological disease indication. 13 January 2025
Belgian biopharmaceutical company UCB has entered into a license agreement with Ailux Biologics, the biologics discovery division of XtalPi, to leverage its AI platform. 9 January 2025
Insilico Medicine, a biotechnology firm specializing in artificial intelligence-powered drug discovery, has raised over $100 million in a series E funding round. 8 January 2025
The market for artificial intelligence (AI) in cancer care is projected to grow from $2.2 billion in 2024 to $6.3 billion by 2029, reflecting a growth rate of 23.1%, according to a recent study by BCC Research. 31 December 2024
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 20 December 2024
Shanghai-based Fangzhou, has entered into a strategic partnership with the Chinese business of Bristol Myers Squibb China, with the goal of enhancing digital platforms for chronic disease management. 19 December 2024
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024